Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:2012:649570.
doi: 10.1155/2012/649570. Epub 2012 Jun 6.

Macrolide therapy in respiratory viral infections

Jin-Young Min  1 , Yong Ju Jang
Affiliations
Review

Macrolide therapy in respiratory viral infections

Jin-Young Min et al. Mediators Inflamm. 2012.

Abstract

Background: Macrolides have received considerable attention for their anti-inflammatory and immunomodulatory actions beyond the antibacterial effect. These two properties may ensure some efficacy in a wide spectrum of respiratory viral infections. We aimed to summarize the properties of macrolides and their efficacy in a range of respiratory viral infection.

Methods: A search of electronic journal articles through PubMed was performed using combinations of the following keywords including macrolides and respiratory viral infection.

Results: Both in vitro and in vivo studies have provided evidence of their efficacy in respiratory viral infections including rhinovirus (RV), respiratory syncytial virus (RSV), and influenza virus. Much data showed that macrolides reduced viral titers of RV ICAM-1, which is the receptor for RV, and RV infection-induced cytokines including IL-1β, IL-6, IL-8, and TNF-α. Macrolides also reduced the release of proinflammatory cytokines which were induced by RSV infection, viral titers, RNA of RSV replication, and the susceptibility to RSV infection partly through the reduced expression of activated RhoA which is an RSV receptor. Similar effects of macrolides on the influenza virus infection and augmentation of the IL-12 by macrolides which is essential in reducing virus yield were revealed.

Conclusion: This paper provides an overview on the properties of macrolides and their efficacy in various respiratory diseases.

PubMed Disclaimer

References

    1. Blasi F, Cazzola M, Tarsia P, Aliberti S, Baldessari C, Valenti V. Telithromycin in lower respiratory tract infections. Future microbiology. 2006;1(supplement 1):7–16. - PubMed
    1. Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Canadian Journal of Veterinary Research. 2010;74(1):1–10. - PMC - PubMed
    1. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clinical Microbiology Reviews. 2010;23(3):590–615. - PMC - PubMed
    1. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. European Respiratory Journal. 1999;13(6):1371–1379. - PubMed
    1. Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax. 1999;54(supplement 2):S58–S62. - PMC - PubMed

MeSH terms

LinkOut - more resources